Editorial

Overweight and Obesity: a global problem requires practical tools

Overweight and obesity are escalating on almost every continent but the prevalence varies markedly among regions and nations. According to the WHO Consultation on Obesity, despite the limited availability of nationally representative data, evidence suggests that the prevalence of overweight and obesity is increasing worldwide at an alarming rate in both developing and developed countries. In many developing countries, obesity coexists with undernutrition. In the United States, recent statistics from the National Health and Nutrition Examination Survey (NHANES) show that between 1994 and 1999, the number of adults who are overweight or obese increased by 5 percent to 61 percent. Almost 108 million adults are either overweight or obese and because of their weight, are at greater risk for several major diseases, including coronary heart disease, hypertension, stroke, diabetes, and cancer.

How Are Overweight and Obesity Measured and Defined?

Although the terms overweight and obesity are often used interchangeably, overweight refers to an excess of body weight compared with height, while obesity refers to an excess of body fat. In populations with high levels of adiposity, excess body fat or adiposity is highly correlated with body weight. Thus, the body mass index, or BMI, which is calculated by dividing weight in kilograms by height in meters squared, is a valid and convenient measure of adiposity. Addi-

continued on page 2

WHL News

19th WHL Council Conference and Workshop on Hypertension & Obesity
Saturday, June 22, 2002
Prague, Czech Republic

Call for Abstracts

We invite you to submit an abstract relating to obesity and hypertension and the accompanying risk factors, as well as efforts on how these problems are being controlled in your population.


There is no specific abstract form. Please type abstract in Microsoft Word, font size 10, single-spaced, and no longer than one page in length. Email is the preferred method of receiving abstracts (gmonhollen@mco.edu). You may also choose to fax (+1-419 383 5360) or mail your abstract to the WHL Secretariat’s Office (for address see impressum). A limited number of posters will be chosen for a brief oral presentation with a question/answer period. All abstracts will be displayed in a poster presentation. There is a restricted number of travel grants available. Please send a written request to the WHL Secretariat.

Contents

<table>
<thead>
<tr>
<th></th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Editorial</td>
<td>1</td>
</tr>
<tr>
<td>Overweight and Obesity: a global problem requires practical tools</td>
<td>1</td>
</tr>
<tr>
<td>WHL News</td>
<td>1</td>
</tr>
<tr>
<td>WHL Council Conference</td>
<td>1</td>
</tr>
<tr>
<td>Control of Hypertension in Portugal</td>
<td>3</td>
</tr>
<tr>
<td>People</td>
<td>4</td>
</tr>
<tr>
<td>Calendar</td>
<td>4</td>
</tr>
</tbody>
</table>
Editorial continued

tional information from NHANES III shows that the prevalence of high blood pressure and mean levels of systolic and diastolic blood pressure increases as BMI increases. The trend of higher prevalence of high blood pressure with increasing BMI is similar for white, black and Mexican-American men and women, but the age-adjusted rates are highest among blacks at every BMI level.

The Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults: Evidence Report released by the National Heart, Lung, and Blood Institute in June 1998 defined overweight as a BMI of 25–29.9 kg/m² and obesity as a BMI of ≥30 kg/m². The guidelines are based on the most extensive review conducted to date of the scientific evidence on overweight and obesity. The review was undertaken by a 24-member Expert Panel, which sought to answer 35 key clinical questions on how different treatment strategies affect weight loss, and how weight control affects the major risk factors for heart disease and stroke, as well as other chronic diseases and conditions. The resulting Guidelines present a new approach for the assessment, classification, and treatment of overweight and obesity while establishing principles of safe and effective weight loss.

What Are the Clinical Guidelines For the Assessment and Treatment of Overweight and Obese Patients?

According to the Clinical Guidelines Evidence Report, treatment of an overweight or obese patient incorporates a two step process: assessment and management. Assessment includes determination of the degree of obesity and overall health status. Management involves not only weight loss and maintenance of body weight but also measures to control other risk factors. Obesity is a chronic disease; thus, patient and practitioner must understand that successful treatment requires a lifelong effort. Convincing evidence supports the benefit of weight loss for reducing blood pressure, lowering blood glucose, and improving dyslipidemias.

Assessment of a patient should include the evaluation of BMI, waist circumference, and overall medical risk. Clinical judgement must be employed when evaluating very muscular patients because BMI may overestimate the degree of fatness in these patients. Excess abdominal fat is an important, independent risk factor for disease. The evaluation of waist circumference to assess obesity or overweight is supported by research. In addition, the measurement of waist-to-hip ratio provides no advantage over waist circumference alone. Men who have waist circumferences greater than 40 inches, and women who have waist circumferences greater than 35 inches, are at higher risk because of excess abdominal fat.

Overall risk must take into account the potential presence of other risk factors. Some conditions associated with obesity place patients at a high risk for subsequent mortality; these will require aggressive modification. Other conditions associated with obesity are less lethal, but still require treatment. The decision to attempt a weight loss treatment should also assess the patient’s readiness to make the necessary lifestyle changes.

Therapy is recommended for patients with a BMI ≥30. It is also recommended for patients with a BMI between 25 and 29.9 or who have a high waist circumference, and 2 or more risk factors. Individuals at lesser risk should be counseled about effective lifestyle changes, if they are ready to change. Therapy begins with lifestyle changes in diet and physical activity. When goals of therapy are not achieved after 6 months, then careful consideration can be given to pharmacotherapy in patients with a BMI ≥30 or a BMI ≥27 with additional risk factors.

What Are the Goals Of Therapy For Weight Loss?

The goals of therapy are to reduce body weight and maintain a lower body weight for the long term; the prevention of further weight gain is the minimum goal. An initial weight loss of 10% of body weight, achieved over six months, is a recommended target. The rate of weight loss should be 1 to 2 pounds each week. Greater rates of weight loss do not achieve better long-term results. After the first six months of weight loss therapy the priority should be weight maintenance, which is achieved through the combined changes in diet, physical activity, and behavior. In some patients, weight loss is not achievable. A goal for these patients should be the prevention of further weight gain, as this would exacerbate disease. Prevention of weight gain can be a successful goal for some of these individuals.
Editorial continued

What Tools Are Available To Help Professionals Treat and Manage Overweight and Obese Patients?

Since the release of the Guidelines, the NHLBI’s Obesity Education Initiative has been striving to help health care practitioners better assess and treat overweight patients. Several practical tools have been designed to be succinct, practical references for the busy health professional and patient. One of the latest tools available is the Practical Guide to the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults developed by the NHLBI in cooperation with the North American Association for the Study of Obesity. It describes how health care practitioners can provide their patients with the direction and support needed to effectively lose weight and keep it off. Based on The Evidence Report, it provides health care practitioners the basic tools necessary to assess and manage overweight and obesity. It includes practical information on dietary therapy, physical activity, and behavior therapy, while also providing guidance on the appropriate use of pharmacotherapy and surgery as treatment options. An innovative feature of the guide is a tear out quick reference guide to help practitioners assess, classify, and treat (ACT) overweight and obese patients. Reproducible tip sheets for patients are included in the guide. The Practical Guide and several other resources for treating overweight and obesity are available through NHLBI and can be found on the Aim for a Healthy Weight website (http://www.nhlbi.nih.gov/health/public/heart/obesity/lose_wt/index.htm).

Many of these publications are available for professionals and the public. They can be ordered online at (http://email.nhlbi.nih.net/dept2.asp?dept_id=OVERWT) or contact the NHLBI Health Information Center at phone (+1) 301-592-8573 or email NHLBIInfo@rover.nhlbi.nih.gov.

Karen Donato, S.M., R.D.
Coordinator, NHLBI Obesity Education Initiative
National Heart, Lung, and Blood Institute
Bldg 31, Rm 4A16, 31 Center Drive, MSC 2480
Bethesda, MD 20892-2480, USA

Phone: (+1) 301-496-1051
Fax: (+1) 301-402-1051
E-mail: donatok@nih.gov

References:

WHL News

Control of Hypertension in Portugal

Professor Fernando de Pádua, President, National Institute for Preventive Cardiology, gave the opening speech at the seminar on Hypertension Management in CINDI (country-wide integrated non communicable disease intervention) participating countries held in Girona, Spain on 21–22 September, 2001. He related his 50+ years of experience in controlling hypertension in Portugal and described the progress made and the challenges of the future. He emphasized the importance of the patient getting involved in their own health care, and the mass media in educating the public in hypertension and other cardiovascular risk factors.

In Portugal, education of the public reduced the very high salt consumption and significantly reduced blood pressure and its complications.
People

In May 2001, Dr. Silja Majahalme was elected president of the Finnish Hypertension Society, Tampere University Hospital, Department of Cardiology, PO Box 2000, 33521 Tampere, Finland.

Phone: (+358) 3 247 5111
Fax: (+358) 3 247 4157
E-mail: silja.majahalme@uta.fi

In September 2001, Professor Bryan Williams was elected president of the British Hypertension Society, University of Leicester, Leicester Royal Infirmary, Clinical Science Building, PO Box 65, Leicester, LE2 7LX, United Kingdom.

Phone: (+44) 116 252 3182
Fax: (+44) 116 252 5847
E-mail: bw17@le.ac.uk

Impressum

The objectives of the WHL are to promote the detection, control and prevention of arterial hypertension in populations. The World Hypertension League (WHL) is a federation of leagues, societies and other national bodies devoted to this goal. Individual membership is not possible. The WHL is a division of the International Society of Hypertension (ISH), and is in official relations with the World Health Organization (WHO).

Secretariat:
Medical College of Ohio, Department of Medicine
3120 Glendale Avenue, Toledo, OH 43614-5809, USA
Phone: (+1) 419 383-6016, Fax: (+1) 419 383 5360
E-mail: gmonhollen@mco.edu
Internet: http://www.mco.edu/whl

Board Officers:
Claude Lenfant (Bethesda), President
Liu Lisheng (Beijing), Vice-President
Peter Sleight (Oxford), Past President
Patrick J. Mulrow (Toledo), Secretary General

Members:
J. George Fodor (Ottawa), Detlev Ganten (Berlin-Buch)
Albert Mimran (Montpellier), K. H. Rahn (Münster)

Advisors to the Board:
Jörg Pötzsch (Berlin-Buch), Communications

The WHL Newsletter is published bimonthly by the World Hypertension League
Anja Kroke, Editor; Erika Pisch, Editorial Assistant

Editorial Office:
Max Delbrück Center for Molecular Medicine (MDC)
Robert-Rössle-Strasse 10, 13125 Berlin-Buch, Germany
Phone: (+49) 30 9489 4533, Fax: (+49) 30 9489 4589
E-mail: whl@mdc-berlin.de
ISSN 1013-1639 Production and distribution:
Georg Thieme Verlag Stuttgart New York

The WHL Newsletter is published with the support of

Calendar

2nd Pan-Hellenic Symposium on Arterial Hypertension & Cardiovascular Risk
March 14–16, 2002
Thessaloniki, Greece
Information: Hellenic Society of Hypertension,
111, Vas. Sofias Ave
11527 Athens, Greece
Fax: (+30) 10 640 0767
Web Site: www.hypertasi.gr

19th World Hypertension League Council Conference and Workshop on Hypertension & Obesity
June 22, 2002
Prague, Czech Republic
Information: Dr. Patrick J. Mulrow
(for address see impressum)

19th Scientific Meeting of the International Society of Hypertension and 12th European Meeting on Hypertension
June 23–27, 2002
Prague, Czech Republic
Information: Guarant Ltd., Opletalova 22
110 00 Prague, Czech Republic
Fax: (+420) 2 84 001 448
E-mail: hypertension@guarant.cz

56th Annual Fall Conference & Scientific Sessions of the Council for High Blood Pressure Research in association with the Council on Kidney in Cardiovascular Disease
September 25–28, 2002
Orlando, FL, USA
Information: Beth Croll, AHA
7272 Greenville Ave,
Dallas, TX 75231, USA
E-mail: beth.croll@heart.org

9th National Scientific Sessions of the Consortium for Southeastern Hypertension Control
October 17–19, 2002
Savannah, GA, USA
Information: COSEHC
Wake Forest University School of Medicine
Medical Center Blvd.
Winston-Salem, NC 27157-1032, USA
Fax: (+1) 336-713-4739
Hotline: (1) 800-267-3421
Web Site: www.cosehc.org